BOULDER, CO / ACCESSWIRE or October 27, 2022 and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care and dermatological conditions, today announced that it has launched Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn® Advanced Skin Repair Cooling Mist direct to consumers for over-the-counter use in the United States.

Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel is a new direct to consumer version of the product previously only available by prescription. Reliefacyn alleviates symptoms such as red bumps, itchy, painful plus scaly rashes, shallow skin fissures and peeling, plus effectively manages symptoms of eczema/atopic dermatitis. Reliefacyn supports the particular three phases of healing (inflammation, proliferation and remodeling), and the gel adheres quickly in order to the pores and skin, making it easy to apply without dripping or running. Reliefacyn will be antipruritic, anti-inflammatory, and anti-allergic.

Rejuvacyn® Sophisticated Skin Repair Cooling Mist is intended for over-the-counter management of minor skin irritations following cosmetic procedures as well as daily epidermis health and hydration. Formulated to enhance the particular body’s natural healing process, Rejuvacyn aids within recovery following common procedures performed at dermatologists’ offices and medical spas such as microdermabrasion, laser treatments, injections, facials, and chemical peels. Rejuvacyn is safe to use around the nose, mouth, and eyes, with a cool mist application that soothes the skin. Rejuvacyn® Advanced Pores and skin Repair Chilling Mist has also been certified as a Natural Personal Care Product by the Natural Products Association.

“We are excited to expand our line of dermatology products to create a portfolio of consumer-focused products that provide healing plus relief with regard to common problems and methods. We’ve also formulated Rejuvacyn as an all-natural product regarding consumers who want in order to avoid potentially harmful additives in their health care regime. Our products will be immediately available through our website, and via third-party distributors, ” said Amy Trombly, CEO associated with Sonoma Pharmaceutical drugs.

For more information about these items, visit . You can order Reliefacyn or Rejuvacyn on our website in or even by contacting our customer service department from 720-452-9690 or [email protected] com .

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader intended for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal treatment, oral care, and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acidity (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and potent properties. Sonoma’s stabilized HOCl immediately relieves itch plus pain, kills pathogens and breaks down biofilm, does not sting or irritate skin plus oxygenates the cells in the particular area treated assisting the body in its home remedies process. You can actually products are sold either directly or even via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado with manufacturing operations in Guadalajara, Mexico. European marketing and sales are usually headquartered within Roermond, Netherlands. More information can be found with . For partnership opportunities, please contact [email protected] com .

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions from the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance associated with Sonoma Drugs, Inc. plus its subsidiaries (the “company”). These forward-looking statements are identified by the use of words like “will be, ” “develop” and “expand, ” among others. Forward-looking claims in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including this kind of risks that will regulatory medical and guideline developments may change, scientific data might not be sufficient to meet regulatory standards or receipt of required regulating clearances or even approvals, scientific results may not be replicated in actual patient settings, protection offered simply by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s items will not be as large as expected, the company’s products will not become able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as questions relative in order to the COVID-19 pandemic and economic advancement, varying product formulations plus a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other dangers detailed from time to time within the company’s filings with the particular Securities plus Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™, Reliefacyn® and Rejuvacyn® are trademarks or registered trademarks associated with Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceutical drugs, Inc.
[email protected] com

SOURCE: Sonoma Drugs, Inc.

View source edition on accesswire. com:

Leave a Reply

Your email address will not be published. Required fields are marked *